Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?

BMC Medicine

Constance Delaugerre¹  Willy Rozenbaum²  Benedicte Loze²  Pierre Charbonneau²  Diane Ponscarme²  Caroline Gatey²  Claire Pintado²  Jean-Michel Molina³ 

[1] Laboratory of Virology, Hopital Saint Louis, AP-HP, Paris, France;Department of Infectious Diseases, Hopital Saint Louis, AP-HP, 1 avenue Claude Vellefaux, Paris 75010, France;INSERM U941, University of Paris Diderot, Sorbonne Paris Cité, Paris, France

关键词: Adherence;    PrEP;    Intermittent;    Men who have sex with men;    Emtricitabine;    Tenofovir;    HIV;   

Others  :  856936
DOI  :  10.1186/1741-7015-11-186

 received in 2013-05-21, accepted in 2013-07-26,  发布年份 2013

【 摘 要 】

Following US Food and Drugs Administration approval in July 2012 of daily oral tenofovir and emtricitabine for pre-exposure prophylaxis (PrEP) to prevent HIV infection in high-risk individuals in the USA, there has been much controversy about the implementation of this PrEP regimen in other countries throughout the world, and in Europe in particular. In this review, we focus on the challenges and opportunities of a daily oral PrEP regimen to curb the rising incidence of HIV infection in high-risk groups, and particularly in men who have sex with men. A number of issues would need to be addressed before PrEP could be implemented, including assessing the real effectiveness and cost-effectiveness of daily PrEP, the sustainability of daily adherence, the risk of selecting resistance, the long-term safety, and the risk of change in sexual behavior that might offset the benefit of PrEP. Alternatives to a daily oral PrEP regimen are being explored.

【 授权许可】

   
2013 Molina et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Miele PS: NDA 21–752 S-030. Truvada (emtricitabine-tenofovir disoproxil fumarate) preexposure prophylaxis indication for prevention of sexually acquired HIV-1. Antiviral drugs advisory committee meeting. 2012. http://www.fda.gov/downloads/advisoryCommittees/committeesMeetingmaterials/drugs/antiviraldrugsadvisorycommittee/UCM305777.pdf webcite
• [2]Colbert JA: Clinical decisions. Preexposure prophylaxis for HIV prevention–polling results. N Engl J Med 2012, 367:e22.
• [3]Krakower DS, Mimiaga MJ, Rosenberger JG, et al.: Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS One 2012, 7:e33119.
• [4]Le Vu S, Le Strat Y, Barin F, et al.: Population based HIV incidence in France 2003–08: a modelling analysis. Lancet Infect Dis 2010, 10:682-687.
• [5]Birrel PJ, Gill ON, Delpech VC, et al.: HIV incidence in men who have sex with men in England and Wales 2001–2010: nationwide population study. Lancet Infect Dis 2013, 13:313-318.
• [6]Le Vu S, Velter A, Meyer L, et al.: Biomarker-based HIV incidence in a community sample of men who have sex with men in Paris. France. PLoS One 2012, 7:e39872.
• [7]Grant RM, Lama JR, Anderson PL, iPrEx Study Team, et al.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363:2587-2599.
• [8]Baeten JM, Donnell D, Ndase P, et al.: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012, 367:399-410.
• [9]Thigpen MC, Kebaabetswe PM, Paxton LA, et al.: Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012, 367:423-434.
• [10]Van Damme L, Corneli A, Ahmed K, et al.: Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012, 367:411-422.
• [11]Marrazzo J, Ramjee G, Nair G, et al.: Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir ge in the VOICE study (MTN 003). Presented at the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta GA, USA: abstract 26LB; 2013.
• [12]Choopanya K, Martin M, Suntharasamai P, et al.: Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013, 381:2083-2090.
• [13]Stone A: Regulatory issues in microbicide development. Geneva, Switzerland: World Health Organization; http://whqlibdoc.who.int/publications/2010/9789241599436_eng.pdf webcite
• [14]Haire B, Kaldor J, Jordens CFC: How good is “good enough” ? The case for varying standards of evidence according to need for new interventions in HIV prevention. American J Bioethics 2012, 12:21-30.
• [15]Bekker LG, Glidden D, Hosek S, et al.: Pre-exposure prophylaxis in young MSM: needs and challenges. Presented at the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta GA, USA: abstract 997; 2013.
• [16]Patterson KB, Prince HA, Kraft E, et al.: Penetration of tenofovir and emtricitabine in mucosal tissues: implication for prevention of HIV-1 transmission. Sci Trans Med 2011, 3:112re4.
• [17]Hughes JP, Baeten JM, Lingappa JR, et al.: Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 2012, 205:358-365.
• [18]Mlisana K, Naicker N, Werner L, et al.: Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis 2012, 206:6-14.
• [19]Liu AY, Vittinghoff E, Sellmeyer DE, et al.: Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One 2011, 6:e23688.
• [20]Pavie J, Rachline A, Loze B, et al.: Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting. PLoS One 2010, 5:e11581.
• [21]Juusola JL, Brandeau ML, Owens DK, Bendavid E: The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med 2012, 156:541-550.
• [22]Gomez GB, Borquez A, Caceres CF, et al.: The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transgender women in Lima. Peru: a mathematical modelling study. PLoS Med 2012, 9:e1001323.
• [23]Adam P, Alexandre A, de Wit J: Perception de la prophylaxie pré-exposition (PrEP) par les internautes gays français. http://www.sneg.org/documents/PREVENTION/SNEG-IPSR-PREP-Rapport-CapoteEtPilule.pdf webcite
• [24]Ware NC, Wyatt MA, Haberer JE, et al.: What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr 2012, 59:463-468.
• [25]Hosek SG, Siberry G, Bell M, et al.: The acceptability and feasibility of an HIV preexposure prophylaxis trial with young men who have sex with men. J Acquir Immune Defic Syndr 2013, 62:447-456.
• [26]Grant R, McMahan V, Amico R, et al.: Drug detection during open-label extension of the iPrEx trial indicates sustained and appropriate interest in PrEP among men who have sex with men. Presented at the 7th IAS Conference on HIV Pathogenesis treatment and Prevention. Kuala Lumpur Malaysia: Abstract WELBC02; 2013.
• [27]Castillo-Mancilla JR, Zheng JH, Rower JE, et al.: Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses 2013, 29:384-390.
• [28]Shah SA, Mullin R, Jones G, et al.: Simultaneous analysis of antiretroviral drugs abacavir and tenofovir in human hair by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2013, 74:308-313.
• [29]García-Lerma JG, Cong ME, Mitchell J, et al.: Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci Transl Med 2010, 2:14ra4.
• [30]On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men who have Sex with Men (IPERGAY). http://clinicaltrials.gov/show/NCT01473472 webcite
• [31]The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP). http://clinicaltrials.gov/show/NCT01327651 webcite
• [32]Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
• [33]Lorente N, Fugon L, Carrieri MP, et al.: Acceptability of an “on demand” pre-exposure HIV prophylaxis trial among men who have sex with men living in France. AIDS Care 2012, 24:468-477.
• [34]Volk JE, Liu A, Vittinghoff E, et al.: Sexual frequency and planning among at-risk men who have sex with men in the United States: implications for event-based intermittent pre-exposure prophylaxis. J Acquir Immune Defic Syndr 2012, 61:112-115.
• [35]Hosek S, Telander K, Balthazar C, et al.: Does sexual behaviour influence adherence to pre-exposure prohylaxis? Data from a pre-exposure prophylaxis trial among young MSM. Presented at the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta GA, USA: abstract 996; 2013.
• [36]Anderson PL, Glidden DV, Liu A, et al.: Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012, 151:151ra125.
• [37]Van’T Klooster G, Hoeben E, Borghys H, et al.: Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother. Antimicrob Agents Chemother 2010, 54:2042-2050.
• [38]Andrews C, Gettie A, Russel-Lodrigue K, et al.: Long-acting parenteral formulation of GSK1265744 protects macaques against repeated intrarectal challenges with SHIV. Presented at the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta GA, USA: abstract 24LB; 2013.
• [39]McCormack S, Fidler S, Fisher M: The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK- International. J STD Aids 2012, 23:1-4.